Parkinson’s disease: A neurodegenerative disease particularly amenable to gene therapy

Molecular Therapy

Volumn 1, Issue 6, 2000, Pages 494-496

  Bohn, Martha C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GDNF PROTEIN, HUMAN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NERVE PROTEIN;

ANIMAL; BRAIN STEM; FOREBRAIN; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN STEM; DOPAMINE; GENE THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROSENCEPHALON;

EID: 0034200627     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1006/mthe.2000.0078     Document Type: Note

References (10)

1. Kordower, J. H., Palfi, S., Chen, E. Y., Ma, S. Y., Sendera, T., Cochran, E. J., Cochran, E. J., Mufson, E. J., Penn, R., Goetz, C. G., and Comella, C. D. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann. Neurol. 46: 419-424.
2. Engele, J., Schubert, D., and Bohn, M. C. (1991). Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: Role of mesencephalic glia. J. Neurosci. Res. 30: 359-371.
3. Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. (1993). GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
4. Bohn, M. C., and Choi-Lundberg, D. L. (1998). Gene therapies for Parkinson’s disease. In Gene Therapy for Neurological Disorders and Brain Tumors (E. A. Chiocca and X. O. Breakefield, Eds.), pp. 377-395. Humana Press, Towata, NJ.
5. Choi-Lundberg, D. L., Lin, Q., Chang, Y.-N., Chiang, Y. L., Hay, C. M., Mohajeri, H., Davidson, B. L., and Bohn, M. C. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275: 838-841.
6. Choi-Lundberg, D. L., Lin, Q., Schallert, T., Crippens, D., Davidson, B. L., Chang, Y.- N., Chiang, Y. L., Qian, J., Bardwaj, L., and Bohn, M. C. (1998). Behavioral and cellular protection of rat dopaminergic neurons elicited by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154: 261-275.
7. Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., and Horellou, P. (1997). Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 94: 8818-8823.
8. Mandel, R. J., Spratt, S. K., Snyder, R. O., and Leff, S. E. (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats. Proc. Natl. Acad. Sci. USA 94: 14083-14088.
9. Kozlowski, D. A., Connor, B., Tillerson, J. L., Schallert, T., and Bohn, M. C. (2000). Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol., in press.
10. Connor, B., Kozlowski, D. A., Schallert, T., Tillerson, J. L., Davidson, B. L., and Bohn, M. C. (1999). Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6: 1936-1951.